Paclitaxel cationic liposomal - CSPC Pharmaceutical Group
Alternative Names: Paclitaxel cationic liposome for injection - CSPC Pharmaceutical GroupLatest Information Update: 28 May 2025
At a glance
- Originator CSPC Pharmaceutical Group
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Breast-cancer in China (Parenteral, Injection)
- 28 May 2025 No recent reports of development identified for phase-I development in Pancreatic-cancer in China (Parenteral, Injection)
- 28 Oct 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (Intra-arterial, Infusion)